NEW YORK (GenomeWeb News) – Hepregen and The Hamner Institutes for Health Sciences today announced a deal aimed at research to be conducted by the two partners.

Under the terms of the agreement, the two entities will carry out R&D work directed at defining the basic concepts "regarding the potential for new microliver products," and new applications and assay methods for Hepregen's existing microliver products.

The research will be led by Edward LeCluyse, associate investigator at Hamner, and Jack McGeehan, Hepregen's VP of Operations.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Science speaks with the University of Michigan's Jedidiah Carlson, who has tracked population genetic discussions at white nationalist sites.

Gene therapies could qualify for a faster US Food and Drug Administration approval process, according to Stat News.

NPR reports that the US House of Representatives has passed a bill to enable terminally ill patients access to experimental drugs.

In Genome Research this week: inversion variants mapped in human, non-human primate genomes; transcriptome profiling of maize, sorghum; and more.